Editing CUA: Overactive Bladder (2017) (section)

== Questions ==

# What is the ICS definition of OAB?
# How does the prevalence of OAB differ between men and women?
# What are the quality of life domains affected by OAB?
# As per the 2017 CUA Guidelines on OAB, what is the recommended work-up of a patient with OAB? Not recommended?
# What are the indications to treat asymptomatic bacteruria? Should a low bacterial count (103–105 CFU/ml) in a patient with OAB be treated?
# When should PVR be evaluated in a patient with suspected OAB?
# When is UDS indicated in a patient with suspected OAB?
# What are the first-line treatment options for OAB?
# What are the second-line treatment options for OAB?
# Which receptors do anti-cholinergics act on in the bladder?
# Which anti-cholinergic agents are available for treatment of OAB in Canada?
# Which anti-cholinergic agents are associated with cognitive impairment?
# Which anti-cholinergic agents should be avoided/require dose adjustment with renal dysfunction? Hepatic dysfunction?
# What are potential adverse events related to the use of anti-cholinergic drugs to treat OAB?
# What are the contraindications to use of anti-cholinergic drugs?
# When should a patient expect symptom improvement after initiating an anti-cholinergic for OAB?
# What are potential adverse events related to the use of beta-3-agonist drugs to treat OAB?
# What are the contraindications to use of beta-3-agonist drugs?
# What is the starting dose for the different drugs used in OAB?
# What are the third-line treatment options for OAB?
# What is the median duration of effect of intradetrusor botox?
# What are potential adverse events related to the use of intradetrusor botox to treat OAB?
# What are the fourth-line treatment options for OAB?
##